Category Press Releases

Celleron Therapeutics Successfully Completes Safety Evaluation of Pioneering Combination Therapy Approach to Treating Colorectal Cancer Oxford, UK, 14th January 2019 – Celleron Therapeutics, the UK-based company developing personalised medicine for cancer patients, has today announced the completion of its Phase…

Celleron Therapeutics appoints Simon Cook as its Clinical Research Director Oxford 14 January 2019; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced today the appointment of Simon Cook as its Clinical Research…

November 12th 2018; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced today the appointment of Dr Shunsheng Zheng as Director of Business Development. Shunsheng has extensive knowledge of licensing and commercialization strategies…

Oxford 1st October 2018;Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced today the appointment of Hao Zhang as Vice President Business Development and Commercialisation. Hao has extensive experience in the Biotech arena,…

Oxford, UK, 20th August 2018 – Celleron Therapeutics, the UK-based company developing personalised medicine for cancer patients, has today announced the initiation and first patient enrolment of its clinical study that will evaluate the effect of a novel combination therapy approach…

The expansion cohort of our Phase I clinical trial is open to patient enrolment.

The company has selected Syneos Health, a leading biopharmaceutical solutions organization, to conduct clinical trials for its lead compound CXD101 in colorectal cancer.

UK MHRA has granted approval for the conduct of a clinical trial with its lead compound CXD101 in colorectal cancer.